The AAJT-S is targeted at reducing deaths from junctional inguinal bleeding in accordance with the August 2011 TCCC guidelines. These bleeds continue to be a significant source of morbidity and mortality on the battlefield. The AAJT-S provides a rapid application of pneumatic compression to the aorta at the abdominal-pelvic junction to occlude blood flow in the inguinal arteries and also in the axilla and other junctional areas.
The AAJT-S is FDA approved for the treatment of junctional haemorrhages.
